Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.

Persson E.

Thromb Res. 2012 May;129 Suppl 2:S51-3. doi: 10.1016/j.thromres.2012.02.033. Epub 2012 Mar 8. Review.

PMID:
22405049
[PubMed - indexed for MEDLINE]
2.

Reversible acylation of factor Xa as a potential therapy for hemophilia.

Lin PH, Laibelman AM, Sinha U.

Thromb Res. 1997 Nov 15;88(4):365-72.

PMID:
9526960
[PubMed - indexed for MEDLINE]
3.

Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.

Schaub RG.

Biochem Pharmacol. 2011 Jul 15;82(2):91-8. doi: 10.1016/j.bcp.2011.03.015. Epub 2011 Mar 29. Review.

PMID:
21453683
[PubMed - indexed for MEDLINE]
4.

Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.

Repke D, Gemmell CH, Guha A, Turitto VT, Broze GJ Jr, Nemerson Y.

Proc Natl Acad Sci U S A. 1990 Oct;87(19):7623-7.

PMID:
2120704
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.

Hilden I, Lauritzen B, Sørensen BB, Clausen JT, Jespersgaard C, Krogh BO, Bowler AN, Breinholt J, Gruhler A, Svensson LA, Petersen HH, Petersen LC, Balling KW, Hansen L, Hermit MB, Egebjerg T, Friederichsen B, Ezban M, Bjørn SE.

Blood. 2012 Jun 14;119(24):5871-8. doi: 10.1182/blood-2012-01-401620. Epub 2012 May 4.

PMID:
22563084
[PubMed - indexed for MEDLINE]
Free Article
6.

Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.

Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P.

Thromb Haemost. 1997 Jun;77(6):1113-9.

PMID:
9241742
[PubMed - indexed for MEDLINE]
7.
8.

Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation.

Hoffman M, Monroe DM, Oliver JA, Roberts HR.

Blood. 1995 Sep 1;86(5):1794-801.

PMID:
7655009
[PubMed - indexed for MEDLINE]
Free Article
9.

Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.

Bolliger D, Szlam F, Molinaro RJ, Escobar MA, Levy JH, Tanaka KA.

Haemophilia. 2010 May;16(3):510-7. doi: 10.1111/j.1365-2516.2009.02164.x. Epub 2009 Dec 29. Erratum in: Haemophilia. 2010 May;16(3):567.

PMID:
20050927
[PubMed - indexed for MEDLINE]
10.

Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.

van 't Veer C, Golden NJ, Mann KG.

Blood. 2000 Feb 15;95(4):1330-5.

PMID:
10666207
[PubMed - indexed for MEDLINE]
Free Article
11.

Potential role of recombinant factor VIIa as a hemostatic agent.

Hedner U, Erhardtsen E.

Clin Adv Hematol Oncol. 2003 Feb;1(2):112-9. Review.

PMID:
16224390
[PubMed - indexed for MEDLINE]
12.

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E; FENOC Study Group.

Blood. 2007 Jan 15;109(2):546-51. Epub 2006 Sep 21.

PMID:
16990605
[PubMed - indexed for MEDLINE]
Free Article
13.

Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex.

Marlu R, Polack B.

Haematologica. 2012 Aug;97(8):1165-72. doi: 10.3324/haematol.2011.055699. Epub 2012 Apr 4.

PMID:
22491732
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors.

Gomperts ED, Astermark J, Gringeri A, Teitel J.

Blood Rev. 2008 Feb;22 Suppl 1:S1-11. doi: 10.1016/S0268-960X(08)70001-8. Review.

PMID:
18485996
[PubMed - indexed for MEDLINE]
15.

Recombinant factor VIIa does not induce hypercoagulability in vitro.

Gallistl S, Cvirn G, Muntean W.

Thromb Haemost. 1999 Feb;81(2):245-9.

PMID:
10064000
[PubMed - indexed for MEDLINE]
16.

Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.

[No authors listed]

CMAJ. 1995 Jul 15;153(2):147-57.

PMID:
7600466
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.

Sørensen B, Ingerslev J.

J Thromb Haemost. 2004 Jan;2(1):102-10.

PMID:
14717973
[PubMed - indexed for MEDLINE]
18.

Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.

Livnat T, Martinowitz U, Zivelin A, Seligsohn U.

Haemophilia. 2008 Jul;14(4):782-6. doi: 10.1111/j.1365-2516.2008.01688.x. Epub 2008 Mar 21.

PMID:
18371162
[PubMed - indexed for MEDLINE]
19.

Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven.

Johannessen M, Andreasen RB, Nordfang O.

Blood Coagul Fibrinolysis. 2000 Apr;11(3):239-42.

PMID:
10870803
[PubMed - indexed for MEDLINE]
20.

Acquired hemophilia: diagnosis and management.

Zakarija A, Green D.

Curr Hematol Rep. 2002 Sep;1(1):27-33. Review.

PMID:
12901122
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk